生命科学资讯

Regulatory actions for Dec. 5, 2025

Money raised by biopharma

Biopharma money raised: Jan. 1-Dec. 4, 2025

BioWorld and Nasdaq stock indices

ACIP drops universal hepatitis B birth dose recommendation

NICE adds further details on how the UK will pay more for drugs

Biopharma money raised by quarter in 2025 (US$M)

Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara

Rapport shares updated results from Phase 2 study of seizure drug

Autoantibody-triggered podocyte membrane budding drives autoimmune kidney disease

Renal PIEZO2 is an essential regulator of renin

A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis

Chutes & Ladders—Yet another CDER leadership shake-up

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA

Cancer blood test developer Freenome to go public in $330M SPAC deal

Biopharma sentiment hit a turning point in October

OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio

Hemophilia gene therapies are struggling on the market, even as innovation soars

ACIP continues to struggle with HBV vaccine scheduling

Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use